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Background: It is important to know the comparative effectiveness of varenicline and nicotine replacement
therapy (NRT) for smoking cessation when prescribed under routine circumstances and in the general population.
Previous estimates relied on cross-sectional data. The objective of the current study was to use longitudinal data to
compare the abstinence rates of smokers trying to stop having used varenicline versus NRT on prescription (Rx)
when provided with minimal professional support in the general population while adjusting for key potential
confounders.
Methods: Prospective cohort study in 270 adults who participated in a household survey, smoked at baseline,
responded to the 6-month follow-up survey, and made at least one quit attempt between the two measurements
with either varenicline or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported
abstinence up to the time of the survey, adjusted for key potential confounders including cigarette dependence
(measured at baseline).
Results: Users of varenicline were younger, reported more time spent with urges to smoke at baseline, and were
less likely to stop abruptly during their last quit attempt (all p < 0.01). The adjusted odds of abstinence in users of
varenicline were 3.83 (95% CI = 1.88-7.77) times higher compared with users of NRT Rx.
Conclusions: Varenicline use with minimal professional support in the general population of smokers appears more
effective than NRT Rx in achieving abstinence.
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cohort studyBackground
Results from a network meta-analysis of randomised con-
trolled trials indicate that varenicline, a partial α4β2 recep-
tor agonist, might be more effective than single form
nicotine replacement therapy (NRT) in achieving short-
term abstinence from smoking [1]. It is important to sup-
plement the evidence from such experimental studies with
evidence from observational studies in the ‘real world’ in
order to establish generalisability.* Correspondence: d.kotz@maastrichtuniversity.nl
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unless otherwise stated.Several cohort studies have been conducted which com-
pared varenicline with NRT, and the majority reported a
higher effectiveness of varenicline [2-9]. However, these
exclusively included clinical samples, e.g. smokers atten-
ding stop-smoking services where they receive specialist
behavioural support. Most use of varenicline involves a
prescription from a clinician with minimal behavioural
support and it is important to assess how far the superior-
ity of varenicline extends to this context.
We previously conducted the only study comparing
varenicline with NRT when prescribed with minimal pro-
fessional support in a representative sample of the general
population, and showed that varenicline was associated
with higher abstinence rates than NRT [10]. However, that
study was limited by its cross-sectional design. In order to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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involving ratings of current urges to smoke assessed at the
time of the survey. In smokers who were abstinent at the
time of the survey these measures served as a proxy for
urges to smoke at the time of the quit attempt, which
seemed to be a valid assumption [12]. It would be advan-
tageous to measure smokers’ level of cigarette dependence
prior to their quit attempt and follow these smokers up
to assess their outcome. We therefore conducted a pro-
spective cohort study in a general population sample
comparing the effectiveness of varenicline with NRT on
prescription (Rx) when provided with minimal profes-
sional support and while adjusting for key potential con-
founding factors measured at baseline.Methods
We used data from the “Smoking Toolkit Study”, which
is an ongoing research programme designed to provide
information about smoking cessation and factors that
promote or inhibit it at a population level [13,14]. Each
month a new sample of approximately 1,800 people aged
16 and over completes a face-to-face computer-assisted
survey, of whom approximately 450 are smokers. The
methods have been described in full elsewhere and have
been shown to result in figures for key variables such as
smoking prevalence that are nationally representative
[13] (www.smokinginengland.info).Study population
For the current study, we used aggregated data from
respondents to the baseline survey in the period from
November 2006 (the start of the survey) to March 2012
(the latest wave of the survey for which 6-month follow-
up data were available), who smoked cigarettes (includ-
ing hand-rolled) or any other tobacco product (e.g., pipe
or cigar) daily or occasionally at the time of the survey.
These respondents were asked if they were happy to be
re-contacted. A follow-up questionnaire was sent to con-
senting respondents 6 months after baseline. Participants
were given £5 ($8) remuneration, and one reminder let-
ter was sent. Of the 27219 smokers at baseline, 5757
(21.2%) were followed up 6 months later. The sample
followed up differed from those not followed-up by be-
ing more likely to be female, older, less motivated to
stop smoking, and reporting higher strengths of urges
to smoke at baseline. The differences were small but
statistically significant.
Respondents to the 6-month follow-up were asked:
“Have you made a serious attempt to stop smoking in
the past 12 months? By serious attempt I mean you
decided that you would try to make sure you never
smoked another cigarette? Please include any attempt
that you are currently making.” We only included thoserespondents who made at least one quit attempt up to
6 months ago.
To identify methods used to stop smoking, respondents
were asked “Which, if any, of the following did you try to
help you stop smoking during the most recent serious quit
attempt?” Respondents could select any of the following:
“nicotine replacement product on prescription or given to
you by a health professional, Champix (varenicline), at-
tended a stop smoking group, attended one or more stop
smoking one-to-one counselling\advice\support session\s,
nicotine replacement product (e.g., patches\gum\inhaler)
without a prescription.”
We identified 379 respondents who used either vareni-
cline or NRT Rx during their most recent quit attempt.
We subsequently excluded respondents who used these
medications in combination with stop smoking group
or one-to-one counselling or NRT over-the-counter
(N = 100), or who had missing data on one or more
of the confounding variables (see next paragraph; N = 9).
This allowed us to perform a complete case analysis in a
sample of 270 smokers at baseline who tried to quit be-
tween baseline and 6-month follow-up with either vareni-
cline or NRT Rx, both of which were assumed to being
prescribed with brief professional advice.
Measurements
Our primary outcome was self-reported non-smoking
up to the time of the 6-month follow-up survey. Respon-
dents were asked: “How long did your most recent serious
quit attempt last before you went back to smoking?”.
Those responding “I am still not smoking” were defined
as non-smokers. Previous research has shown that self-
reported abstinence in surveys of this kind closely reflects
true smoking rates and is not subject to the kind of biases
observed in clinical trials where there is social pressure to
claim abstinence [15,16].
We measured variables that are potentially associated
with the use of smoking cessation treatments and that
may also have an effect on abstinence. These potential
confounders were chosen a priori. The most important
factor was cigarette dependence for which we used two
questions measured at baseline. First, time spent with
urges to smoke was assessed by asking: “How much of
the time have you felt the urge to smoke in the past
24 hours? Not at all (coded 1), a little of the time (2),
some of the time (3), a lot of the time (4), almost all of
the time (5), all of the time (6)”. Second, strength of
urges to smoke was measured by asking “In general, how
strong have the urges to smoke been?”: slight (1), moder-
ate (2), strong (3), very strong (4), extremely strong (5).
This question was coded “0” for smokers who responded
“not at all” to the previous question. Different measures of
dependence exist but urges to smoke have been found to
be a better predictor of relapse than the more common
Table 1 Associations between sample characteristics and
use of varenicline or NRT Rx
Variable Varenicline NRT Rx P
(N = 118) (N = 152)
Non-smoker at follow-up 39.8 (47) 19.7 (30) <0.001
Age at baseline, mean (SD) 46.0 (12.2) 51.7 (13.8) <0.001
Female sex 57.6 (68) 56.6 (86) 0.863
Social grade
AB 2.5 (3) 10.5 (16) <0.001
C1 29.7 (35) 17.8 (27)
C2 23.7 (28) 11.8 (18)
D 22.0 (26) 18.4 (28)
E 22.0 (26) 41.4 (63)
Number of quit attempts
prior to the most recent
one at follow-up
0 83.1 (98) 73.0 (111) 0.147
1 12.7 (15) 19.7 (30)
2 4.2 (5) 7.2 (11)
Time since last quit attempt
started at follow-up
<=1 week 7.6 (9) 9.2 (14) 0.097
1–4 weeks 8.5 (10) 13.8 (21)
4–8 weeks 22.0 (26) 18.4 (28)
8–12 weeks 22.0 (26) 31.6 (48)
12–26 weeks 39.8 (47) 27.0 (41)
Stopped abruptly during last
quit attempt at follow-up
(versus cut down first)
35.6 (42) 52.0 (79) 0.007
Time spent with urges to
smoke at baseline, mean (SD)
3.6 (1.3) 3.2 (1.1) 0.006
Strength of urges to smoke
at baseline, mean (SD)
2.4 (1.1) 2.3 (1.0) 0.481
Figures are presented as percentage within varenicline/NRT Rx (N), unless
stated otherwise. Time spent with urges to smoke: 1 (not at all) to 6 (all the
time). Strength of urges to smoke: 0 (no urges) to 5 (extremely strong urges).
NRT Rx = nicotine replacement therapy on prescription. Social grade:
AB = managerial and professional occupations, C1 = intermediate occupations,
C2 = small employers and own account workers, D = lower supervisory and
technical occupations, and E = semi-routine and routine occupations, never
workers, and long-term unemployed.
Table 2 Unadjusted and adjusted odds of self-reported
non-smoking at 6-month follow-up, stratified by use of
varenicline or NRT Rx
OR (95% CI)




Varenicline (N = 118) 2.70 (1.56-4.64) 3.83 (1.88-7.77)
NRT Rx (reference) (N = 152) 1 1
†Odds ratio (OR) adjusted for age, sex, social grade, time since last quit
attempt started, number of quit attempts prior to the one in question,
stopping abruptly versus cutting down, time spent with urges to smoke,
strength of urges to smoke, and year of the survey. 95% CI = 95% confidence
interval around OR. NRT Rx = nicotine replacement therapy on prescription.
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ponents in this particular population [11]. Demographic
characteristics we took into account were age, sex, and so-
cial grade (AB = managerial and professional occupations,
C1 = intermediate occupations, C2 = small employers and
own account workers, D = lower supervisory and tech-
nical occupations, and E = semi-routine and routine occu-
pations, never workers, and long-term unemployed). With
regard to the most recent quit attempt measured at 6-
month follow-up, we asked the time since this quit at-
tempt was initiated; the number of quit attempts prior to
this attempt that occurred since baseline; and whether re-
spondents cut down first or stopped abruptly without cut-
ting down.
Data analysis
The simple associations between potential confounders
and use of varenicline vs. NRT Rx were assessed with
ANOVA for continuous variables and Pearson’s χ2 for
categorical variables.
For the primary analysis, we used a multiple logistic
regression model in which we regressed the outcome
measure (self-reported non-smoking at 6-month follow-
up compared with smoking) on the effect measure (vare-
nicline vs. NRT Rx), adjusted for the above mentioned
potential confounders and year of the survey.
Results
Among the study sample of 270 respondents 193 (71.5%)
reported smoking and 77 (28.5%) reported non-smoking
at the 6-month follow-up survey. A total of 118 (43.7%)
respondents had used varenicline and 152 (56.3%) NRT
Rx during their most recent quit attempt. The unadjusted
abstinence rates were 39.8% (N = 47) for users of vareni-
cline and 19.7% (N = 30) for users of NRT Rx.
Associations between characteristics of the sample and
use of varenicline or NRT Rx are presented in Table 1.
Users of varenicline were younger, reported more time
spent with urges to smoke at baseline, and were less likely
to stop abruptly during their most recent quit attempt at
follow-up. Users of varenicline and NRT Rx also differed
by social grade, but this difference was non-linear.
The results of our primary analysis are presented in
Table 2. The adjusted odds of non-smoking in users of
varenicline were 3.83 (95% CI = 1.88-7.77) times higher
compared with users of NRT Rx.
Discussion
In this prospective cohort study in a representative sam-
ple of smokers from the English general population, use
of varenicline during a quit attempt was associated with
a higher rate of success of achieving abstinence com-
pared with NRT Rx.
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cline versus NRT Rx in our current study (OR = 3.83) was
larger than estimated from previous studies, but our sam-
ple size was relatively small and the confidence intervals
(1.88-7.77) overlap with previous estimates. The largest
randomised controlled trial directly comparing varenicline
with single form NRT reported an odds ratio of 1.70 at the
end of treatment [17], which is close to the lower bound of
our the confidence interval. Two cohort studies directly
compared varenicline with single form NRT, and reported
odds ratios of 1.78 at four weeks after the target quit date
[4] and 2.03 at 52 weeks [6].
Our study has several limitations. First, the response
to our 6-month follow-up was only 21%, and the res-
ponse also differed slightly by demographic and smoking
characteristics. A higher response would have resulted in
increased statistical power, but our sample was large
enough to statistically detect the differences in success
rates between users of varenicline and NRT Rx. There is
no clear mechanism by which non-response bias could
have influenced the findings, and the fact that the findings
support clinical trial data and data from other real-world
settings suggests such bias is unlikely to be a major factor.
Second, non-randomised studies are generally vulnerable
to confounding. We reduced this risk further than many
previous studies by adjusting for tobacco dependence and
several other potential confounders. Our rating of urges to
smoke is a valid measure of dependence as it predicts suc-
cess at stopping smoking better than the more common
Fagerström Test for Nicotine Dependence in the popula-
tion we are studying (smokers in England) [11]. However,
residual confounding may have occurred as not all factors
associated with self-selection of treatment were measured
in our survey, such as previous use of NRT or varenicline
during a quit attempt, co-morbidity [18] or psychological
distress [19]. Third, our self-reported outcome measure of
abstinence from smoking was not biochemically validated.
In observational studies like ours, however, it is unlikely
that misreporting of abstinence is associated with the type
of treatment respondents used during the last quit at-
tempt they recall [15,16]. Fourth, we did not have data on
whether NRT users were using one form only or more
than one form. The results from two other cohort studies
indicate that varenicline may not be substantially more ef-
fective than dual form NRT [3,8]. It may be that most of
our NRT users were using a single form, and that if they
used more than one form the difference from varenicline
would be reduced or eliminated. Fifth, most of the res-
pondents followed up had only quit for a few weeks or
months. It is possible that the difference between NRT
and varenicline is reduced longer term. A further limita-
tion is that we did not have data on actual use of, and ad-
herence to, the medication. However, findings from this
same data set have found that NRT Rx increases successrates relative to no use of medication by an amount
that is in line with results from clinical trials so it seems
unlikely that low NRT adherence in this setting would
have made a significant contribution to the difference
from varenicline. Finally, we did not have data on the
actual behavioural support smokers received. We ex-
cluded respondents who used varenicline or NRT in
combination with stop smoking group or one-to-one
counselling. Hence, we found it reasonable to assume
that these medications were prescribed with minimal
professional support. Nevertheless, there still might be
slight variations in the minimal professional support
smokers received. If, hypothetically, such minimal sup-
port would be systematically “better” in users of vareni-
cline (e.g., in terms of instructions on how to use the
medication), this would overestimate the effectiveness
of this medication compared with NRT.
As far as we are aware our study is the first prospect-
ive cohort study in a general population sample directly
comparing the effectiveness of varenicline with NRT Rx
when provided with minimal professional support. Our
study included all smokers aged 16 years or older who
made a quit attempt, including those who smoke less
than 10 cigarettes per day - a subgroup that constitutes
one third of current smokers in England [20] and is usu-
ally excluded from clinical trials.
Conclusion
In conclusion, this longitudinal study provided further
support for a benefit of varenicline compared with NRT
Rx as used by the general population of smokers with
limited behavioural support. Future research should ad-
dress the comparative effectiveness in the long term.
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